NDAORALTABLETPriority Review
Approved
May 1983
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Priority Review
LITHOSTAT (acetohydroxamic acid) by Mission Therapeutics is urease inhibitors [moa]. First approved in 1983.
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LITHOSTAT (acetohydroxamic acid) is an oral urease inhibitor approved in 1983 for the management of struvite kidney stones by reducing urease-producing bacterial activity. It works by inhibiting the enzyme urease, which prevents the formation of alkaline urine that promotes stone crystal formation. This niche mechanism addresses a specific urological condition with limited therapeutic alternatives.
$0.572MPart D
LOE ApproachingDeclining commercial interest with minimal Part D spend ($572K in 2023) signals a small, legacy franchise with limited team expansion opportunities.
Mechanism of Action
Urease Inhibitors
Pharmacologic Class:
Urease Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LITHOSTAT represents a late-stage, niche product career opportunity with minimal growth trajectory and limited visibility; roles focus on maintenance of a small installed base rather than expansion or innovation. Career development on this legacy product is constrained by flat commercial metrics, zero linked job openings, and absence of clinical pipeline activity.
Product Manager
Worked on LITHOSTAT at Mission Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.